HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zion deploys Acne Terminator

This article was originally published in The Rose Sheet

Executive Summary

Featuring "high-grade" Calcium Montmorillonite clay, Acne Terminator dissolves acne without damaging skin as prescription medicines often do, according to San Francisco-based Zion Health. Called "Kanwa" by African tribes, the clay contains more than 60 trace minerals and "has a negative charge, pulling bacteria out of the skin and absorbing waste without irritating the skin," the firm says. "Prescription acne treatments frequently produce harsh side effects including burning, redness, itching, skin infections, rashes, nausea and vomiting," Zion asserts, noting also that benzoyl peroxide, used in "most" OTC acne products, is "commonly known to dry the skin and stop working after a short period of time." Acne Terminator, on the other hand, can be used effectively "for a long period of time." Product also contains salicylic acid derived from willow bark; it retails for $23.99 at KanwaMinerals.com and selected health food stores

You may also be interested in...

Biosimilars: US FDA Considering ‘Guardrails’ To Prevent Misinformation

Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.

Medicare Retail Drug Spending Accelerates In 2018 Despite Price Declines

Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.

Pfizer's Bourla: "I Think We Forgot What It Looks Like To Grow"

The big pharma CEO reflected on his first year of leadership at Pfizer during the Forbes Healthcare Summit and talked about executing on a plan to deliver 6% growth through 2026. 



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts